Latest Conference Articles

April 30th 2015, 11:52am

MDS Symposium

HLA-matched allogeneic hematopoietic stem cell transplantation was associated with more than a doubling in 4-year overall survival rates for patients with intermediate-2 or high-risk myelodysplastic syndromes.

April 30th 2015, 10:29am

MDS Symposium

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

April 30th 2015, 7:30am

MDS Symposium

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.

April 30th 2015, 5:22am

MDS Symposium

The first-in-class activin receptor antagonist sotatercept stimulated erythropoiesis in nearly half of patients with MDS and non-proliferative CMML following failure on erythropoiesis-stimulating agents.

April 28th 2015, 1:54pm

MDS Symposium

Interview with Thomas Prebet MD, PhD, in advance of the 2015 International MDS Symposium, on topics related to supportive care in MDS and iron chelation therapy.

April 28th 2015, 8:02am

Oncology Nursing Society Congress

Portal vein thrombosis is a dangerous and often overlooked side effect of certain gastrointestinal malignancies such as liver and pancreatic cancer, that oncology nurses need to be more proactive in managing.

April 23rd 2015, 8:34am

AACR Annual Meeting

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

April 22nd 2015, 11:24am

AACR Annual Meeting

Robert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.

April 22nd 2015, 11:01am

AACR Annual Meeting

The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.

April 22nd 2015, 10:38am

AACR Annual Meeting

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

April 21st 2015, 12:23pm

AACR Annual Meeting

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

April 21st 2015, 11:29am

AACR Annual Meeting

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

April 21st 2015, 8:44am

AACR Annual Meeting

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

April 21st 2015, 7:32am

AACR Annual Meeting

James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

April 21st 2015, 6:11am

AACR Annual Meeting

HPV vaccination may offer protection against HPV-related cancers across multiple tumor sites in women aged 18-25 who had been previously exposed to HPV.

April 20th 2015, 12:39pm

AACR Annual Meeting

Frontline immunotherapy with nivolumab plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma.

April 20th 2015, 10:19am

AACR Annual Meeting

F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

April 20th 2015, 8:56am

AACR Annual Meeting

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.

April 20th 2015, 7:32am

AACR Annual Meeting

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

April 20th 2015, 7:25am

AACR Annual Meeting

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.